We thank Gupta and colleagues for their comments on our article1. We read with interest the recommendations by the Australasian Psoriasis Collaboration of specified dosing with methotrexate Mondays and folate Fridays. This is an extension to the “name the day” recommendation set out by the Therapeutic Goods Administration in 1998.2 However, there are concerns with naming Mondays, as this has been mistaken for “mornings” and has been the cause of previous daily dosing errors.3 We welcome any efforts aimed at reducing inadvertent daily dosing; however, as outlined in our article, we believe that more needs to be done. Despite the fact that the recommendations of the Australasian Psoriasis Collaboration were released in 2014, we have seen an increase in dosing errors reported to the Australian Poisons Centres in 2014–2015.
Publication of your online response is subject to the Medical Journal of Australia's editorial discretion. You will be notified by email within five working days should your response be accepted.